News

Biotech executive, Barbara J. Jones, Ph.D., has been named Chief Executive Officer of the Clinical and Laboratory Standards Institute (CLSI) effective May 16, 2022. The current CLSI CEO, Glen Fine, announced his retirement in January 2022 and is set to depart the organization after 17 years at the helm.

The Clinical and Laboratory Standards Institute (CLSI) has published M100—Performance Standards for Antimicrobial Susceptibility Testing, 32nd Edition.

CLSI announces the election of three new Board members. Serving as new Directors are Collette Fitzgerald, PhD, Tania Motschman, MS, MT(ASCP)SBB, and Susan Sharp, PhD, D(ABMM), F(AAM).

The Clinical and Laboratory Standards Institute (CLSI) has published the 5th edition of M39—Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data. This guideline describes methods for recording and analyzing antimicrobial susceptibility test data, consisting of cumulative and ongoing summaries of susceptibility patterns of clinically significant microorganisms.

The Clinical and Laboratory Standards Institute announces the recipients of its 2022 Excellence Awards. These awards celebrate the achievements of CLSI volunteers who have helped improve the quality of medical care worldwide.

The Clinical and Laboratory Standards Institute (CLSI) has published the first edition of guideline EP39—A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of In Vitro Medical Laboratory Tests.

The Clinical and Laboratory Standards Institute (CLSI) has published the first edition of H62—Validation of Assays Performed by Flow Cytometry.

Glen Fine, the Chief Executive Officer of the Clinical and Laboratory Standards Institute (CLSI), announced he’s retiring effective Spring 2022. For 17 years Fine has served as the head of the globally recognized standards development organization in the field of laboratory medicine.

Read CLSI publishes new guideline MM24—Molecular Methods for Genotyping and Strain Typing of Infectious Organisms and other press releases.

Read CLSI publishes new guideline NBS09—Newborn Screening for X-Linked Adrenoleukodystrophy and other press releases.